Incyte’s Jakafi Flunks In Phase III Myelofibrosis Study As Loss Of Exclusivity Nears

 
• By Alaric DeArment
  
Incyte said 6 March that it would discontinue the Phase III LIMBER-304 study • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D